Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 3/2009

01-04-2009

Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases

Authors: G. Denas, F. Marzot, P. Offelli, A. Stendardo, U. Cucchini, R. Russo, G. Nante, S. Iliceto, Vittorio Pengo

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2009

Login to get access

Abstract

Background Timely reversal of excessive anticoagulation is important in preventing bleeding complications. The use of vitamin K in correcting over-anticoagulation is widely accepted to be superior to discontinuation of therapy but its effectiveness and safety in large scale cohort studies has not been assessed. Methods According to our protocol, 2 mg of oral vitamin K in addition to omitting the day’s dose of warfarin, were administered to all patients presenting INR levels ≥5.0 and below 10.0; the INR values were checked 20 h after vitamin K administration. The rate of decay of INR, bleeding and thromboembolic complications at presentation and the following 30 days, as well as resistance to warfarin were assessed. Results Of the 1,611 events, 1,043 (878 patients) met the selection criteria. The median (interquartile range) INR was 6.64 (6.12–7.52) at presentation (day zero) and fell to a median (interquartile range) INR of 2.72 (2.18–3.52, P < 0.0001) after the vitamin K administration (day one) and 90.6% of the INRs were below 4.5. In 98 (9.4%) instances the INR values did not fall below the safe limit of 4.5 and in 173 (17%) instances the INR values were overcorrected to below 2.0. Median INR value on day zero in these two groups was higher (7.3 vs. 6.6, P < 0.0001) and lower (6.5 vs. 6.7, P = 0.049) than that of the remaining cases, respectively. Overcorrection occurred more frequently in women (P = 0.0002). Female gender was an independent factor associated with INR overcorrection (P = 0.001; OR = 1.7, 95% CI 1.3–2.3). The INRs on day one were inside, above and below the therapeutic range in 44%, 36% and 20% respectively. Warfarin resistance was observed in six cases (0.6%). Major bleeding was reported in one case (1.1 per 100 patient-years), minor bleeding in 14 cases (16.1 per 100 patient-years) and thromboembolic events in six high risk patients (6.9 per 100 patient-years) during the one month period following vitamin K administration. Conclusions This adopted protocol for the reversal of excessive anticoagulation in asymptomatic or minor symptom presenting patients is easily applied, effective in lowering the INR and preventing complications. Its use in high risk thromboembolic patients warrants caution.
Literature
1.
go back to reference Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH (2001) Characteristics of anticoagulant therapy, comorbidity related to overanticoagulation. Thromb Haemost 86:569–574, 01080569 [pii]PubMed Penning-van Beest FJ, van Meegen E, Rosendaal FR, Stricker BH (2001) Characteristics of anticoagulant therapy, comorbidity related to overanticoagulation. Thromb Haemost 86:569–574, 01080569 [pii]PubMed
2.
go back to reference Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:204S–233S, 10.1378/chest.126.3_suppl.204SPubMedCrossRef Ansell J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E (2004) The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126:204S–233S, 10.1378/chest.126.3_suppl.204SPubMedCrossRef
3.
go back to reference van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E (1993) Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153:1557–1562, 10.1001/archinte.153.13.1557PubMedCrossRef van der Meer FJ, Rosendaal FR, Vandenbroucke JP, Briet E (1993) Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153:1557–1562, 10.1001/archinte.153.13.1557PubMedCrossRef
4.
go back to reference Hylek EM, Chang Y, Skates SJ, Hughes RA, Singer DE (2000) Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 160:1612–1617, 10.1001/archinte.160.11.1612PubMedCrossRef Hylek EM, Chang Y, Skates SJ, Hughes RA, Singer DE (2000) Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch Intern Med 160:1612–1617, 10.1001/archinte.160.11.1612PubMedCrossRef
5.
go back to reference Poller L, Shiach CR, MacCallum PK, Johansen AM, Munster AM, Magalhaes A, Jespersen J (1998) Multicentre randomised study of computerised anticoagulant dosage. European concerted action on anticoagulation. Lancet 352:1505–1509, S0140673698041476 [pii]PubMedCrossRef Poller L, Shiach CR, MacCallum PK, Johansen AM, Munster AM, Magalhaes A, Jespersen J (1998) Multicentre randomised study of computerised anticoagulant dosage. European concerted action on anticoagulation. Lancet 352:1505–1509, S0140673698041476 [pii]PubMedCrossRef
6.
go back to reference Pengo V, Banzato A, Garelli E, Zasso A, Biasiolo A (1993) Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis 4:739–741PubMedCrossRef Pengo V, Banzato A, Garelli E, Zasso A, Biasiolo A (1993) Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis 4:739–741PubMedCrossRef
7.
go back to reference Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11–17, 10.1056/nejm199507063330103PubMedCrossRef Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJM, Vandenbroucke JP, Briet E (1995) Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 333:11–17, 10.1056/nejm199507063330103PubMedCrossRef
8.
go back to reference Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J (1998) Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 79:1116–1118, 98061116 [pii]PubMed Crowther MA, Donovan D, Harrison L, McGinnis J, Ginsberg J (1998) Low-dose oral vitamin K reliably reverses over-anticoagulation due to warfarin. Thromb Haemost 79:1116–1118, 98061116 [pii]PubMed
9.
go back to reference DeZee KJ, Shimeall WT, Douglas KM, Shumway NM, O’Malley PG (2006) Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 166:391–397, 10.1001/.391PubMedCrossRef DeZee KJ, Shimeall WT, Douglas KM, Shumway NM, O’Malley PG (2006) Treatment of excessive anticoagulation with phytonadione (vitamin K): a meta-analysis. Arch Intern Med 166:391–397, 10.1001/.391PubMedCrossRef
10.
go back to reference Hanslik T, Prinseau J (2004) The use of vitamin K in patients on anticoagulant therapy: a practical guide. Am J Cardiovasc Drugs 4:43–55, 415 [pii]PubMedCrossRef Hanslik T, Prinseau J (2004) The use of vitamin K in patients on anticoagulant therapy: a practical guide. Am J Cardiovasc Drugs 4:43–55, 415 [pii]PubMedCrossRef
11.
go back to reference Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS (2000) Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 20:1159–1166PubMedCrossRef Patel RJ, Witt DM, Saseen JJ, Tillman DJ, Wilkinson DS (2000) Randomized, placebo-controlled trial of oral phytonadione for excessive anticoagulation. Pharmacotherapy 20:1159–1166PubMedCrossRef
12.
go back to reference Wilson SE, Watson HG, Crowther MA (2004) Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review. CMAJ 170:821–824PubMed Wilson SE, Watson HG, Crowther MA (2004) Low-dose oral vitamin K therapy for the management of asymptomatic patients with elevated international normalized ratios: a brief review. CMAJ 170:821–824PubMed
13.
go back to reference Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423–428PubMedCrossRef Palareti G, Leali N, Coccheri S, Poggi M, Manotti C, D’Angelo A, Pengo V, Erba N, Moia M, Ciavarella N, Devoto G, Berrettini M, Musolesi S (1996) Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348:423–428PubMedCrossRef
14.
go back to reference Wittkowsky AK (2005) Factors associated with INR elevation and bleeding complications during warfarin therapy. Arch Intern Med 165:703, 10.1001/archinte.165.6.703-aPubMedCrossRef Wittkowsky AK (2005) Factors associated with INR elevation and bleeding complications during warfarin therapy. Arch Intern Med 165:703, 10.1001/archinte.165.6.703-aPubMedCrossRef
15.
go back to reference Bussey HI, Chiquette E, Bianco TM, Lowder-Bender K, Kraynak MA, Linn WD, Farnett L, Clark GM (1997) A statistical and clinical evaluation of fingerstick and routine laboratory prothrombin time measurements. Pharmacotherapy 17:861–866PubMed Bussey HI, Chiquette E, Bianco TM, Lowder-Bender K, Kraynak MA, Linn WD, Farnett L, Clark GM (1997) A statistical and clinical evaluation of fingerstick and routine laboratory prothrombin time measurements. Pharmacotherapy 17:861–866PubMed
16.
go back to reference Smith JK, Aljazairi A, Fuller SH (1999) INR elevation associated with diarrhea in a patient receiving warfarin. Ann Pharmacother 33:301–304, 10.1345/aph.18171PubMedCrossRef Smith JK, Aljazairi A, Fuller SH (1999) INR elevation associated with diarrhea in a patient receiving warfarin. Ann Pharmacother 33:301–304, 10.1345/aph.18171PubMedCrossRef
17.
go back to reference Sconce EA, Kamali F (2006) Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. Eur J Haematol 77:457–462, EJH763 [pii] 10.1111/j.0902-4441.2006.t01-1-EJH2957.xPubMedCrossRef Sconce EA, Kamali F (2006) Appraisal of current vitamin K dosing algorithms for the reversal of over-anticoagulation with warfarin: the need for a more tailored dosing regimen. Eur J Haematol 77:457–462, EJH763 [pii] 10.1111/j.0902-4441.2006.t01-1-EJH2957.xPubMedCrossRef
18.
go back to reference Schirger A, Spittel JA Jr, Ragen PA (1959) Small doses of vitamin K1 for correction of reduced prothrombin activity. Proc Staff Meet Mayo Clin 34:453–458PubMed Schirger A, Spittel JA Jr, Ragen PA (1959) Small doses of vitamin K1 for correction of reduced prothrombin activity. Proc Staff Meet Mayo Clin 34:453–458PubMed
19.
go back to reference Taylor CT, Chester EA, Byrd DC, Stephens MA (1999) Vitamin K to reverse excessive anticoagulation: a review of the literature. Pharmacotherapy 19:1415–1425PubMedCrossRef Taylor CT, Chester EA, Byrd DC, Stephens MA (1999) Vitamin K to reverse excessive anticoagulation: a review of the literature. Pharmacotherapy 19:1415–1425PubMedCrossRef
20.
go back to reference Ortin M, Olalla J, Marco F, Velasco N (1998) Low-dose vitamin K1 versus short-term with holding of acenocoumarol in the treatment of excessive anticoagulation episodes induced by acenocoumarol. A retrospective comparative study. Haemostasis 28:57–61, hae28057 [pii]PubMed Ortin M, Olalla J, Marco F, Velasco N (1998) Low-dose vitamin K1 versus short-term with holding of acenocoumarol in the treatment of excessive anticoagulation episodes induced by acenocoumarol. A retrospective comparative study. Haemostasis 28:57–61, hae28057 [pii]PubMed
22.
go back to reference Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D (2003) Comparison of oral vs intravenous phytonadione (Vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 163:2469–2473, 10.1001/archinte.163.20.2469PubMedCrossRef Lubetsky A, Yonath H, Olchovsky D, Loebstein R, Halkin H, Ezra D (2003) Comparison of oral vs intravenous phytonadione (Vitamin K1) in patients with excessive anticoagulation: a prospective randomized controlled study. Arch Intern Med 163:2469–2473, 10.1001/archinte.163.20.2469PubMedCrossRef
23.
go back to reference Fiore LD, Scola MA, Cantillon CE, Brophy MT (2001) Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 11:175–183PubMedCrossRef Fiore LD, Scola MA, Cantillon CE, Brophy MT (2001) Anaphylactoid reactions to vitamin K. J Thromb Thrombolysis 11:175–183PubMedCrossRef
24.
go back to reference Wjasow C, McNamara R (2003) Anaphylaxis after low dose intravenous vitamin K. J Emerg Med 24:169–172, S0736467902007205 [pii]PubMedCrossRef Wjasow C, McNamara R (2003) Anaphylaxis after low dose intravenous vitamin K. J Emerg Med 24:169–172, S0736467902007205 [pii]PubMedCrossRef
25.
go back to reference Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, Venco A, Ageno W (2002) Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 137:251–254, 200208200-00009 [pii]PubMed Crowther MA, Douketis JD, Schnurr T, Steidl L, Mera V, Ultori C, Venco A, Ageno W (2002) Oral vitamin K lowers the international normalized ratio more rapidly than subcutaneous vitamin K in the treatment of warfarin-associated coagulopathy. A randomized, controlled trial. Ann Intern Med 137:251–254, 200208200-00009 [pii]PubMed
26.
go back to reference Lousberg TR, Witt DM, Beall DG, Carter BL, Malone DC (1998) Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med 158:528–534, 10.1001/archinte.158.5.528PubMedCrossRef Lousberg TR, Witt DM, Beall DG, Carter BL, Malone DC (1998) Evaluation of excessive anticoagulation in a group model health maintenance organization. Arch Intern Med 158:528–534, 10.1001/archinte.158.5.528PubMedCrossRef
27.
go back to reference Sconce E, Avery P, Wynne H, Kamali F (2007) Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109:2419–2423, 10.1182/blood-2006-09-049262PubMedCrossRef Sconce E, Avery P, Wynne H, Kamali F (2007) Vitamin K supplementation can improve stability of anticoagulation for patients with unexplained variability in response to warfarin. Blood 109:2419–2423, 10.1182/blood-2006-09-049262PubMedCrossRef
28.
go back to reference Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L, Schnurr T, McGinnis J, Gent M, Hirsh J, Ginsberg J (2000) Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 356:1551–1553, S0140673600031251 [pii]PubMedCrossRef Crowther MA, Julian J, McCarty D, Douketis J, Kovacs M, Biagoni L, Schnurr T, McGinnis J, Gent M, Hirsh J, Ginsberg J (2000) Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 356:1551–1553, S0140673600031251 [pii]PubMedCrossRef
29.
go back to reference Hylek EM, Singer DE (1994) risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120:897–902PubMed Hylek EM, Singer DE (1994) risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 120:897–902PubMed
30.
go back to reference Palareti G, Hirsh J, Legnani C, Manotti C, D’Angelo A, Pengo V, Moia M, Guazzaloca G, Musolesi S, Coccheri S (2000) Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 160:470–478, 10.1001/archinte.160.4.470PubMedCrossRef Palareti G, Hirsh J, Legnani C, Manotti C, D’Angelo A, Pengo V, Moia M, Guazzaloca G, Musolesi S, Coccheri S (2000) Oral anticoagulation treatment in the elderly: a nested, prospective, case-control study. Arch Intern Med 160:470–478, 10.1001/archinte.160.4.470PubMedCrossRef
31.
go back to reference Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH, for the Warfarin Optimized Outpatient Follow-up Study G (1993) Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 118:511–520PubMed Fihn SD, McDonell M, Martin D, Henikoff J, Vermes D, Kent D, White RH, for the Warfarin Optimized Outpatient Follow-up Study G (1993) Risk factors for complications of chronic anticoagulation: a multicenter study. Ann Intern Med 118:511–520PubMed
32.
go back to reference Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95:315–328PubMedCrossRef Landefeld CS, Beyth RJ (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95:315–328PubMedCrossRef
33.
go back to reference Baker P, Gleghorn A, Tripp T, Paddon K, Eagleton H, Keeling D (2006) Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. Br J Haematol 133:331–336, BJH6029 [pii].1111/j.1365-2141.2006.06029.xPubMedCrossRef Baker P, Gleghorn A, Tripp T, Paddon K, Eagleton H, Keeling D (2006) Reversal of asymptomatic over-anticoagulation by orally administered vitamin K. Br J Haematol 133:331–336, BJH6029 [pii].1111/j.1365-2141.2006.06029.xPubMedCrossRef
35.
go back to reference Kearon C, Hirsh J (1997) Management of anticoagulation before and after elective surgery. N Engl J Med 336:1506–1511, 10.1056/nejm199705223362107PubMedCrossRef Kearon C, Hirsh J (1997) Management of anticoagulation before and after elective surgery. N Engl J Med 336:1506–1511, 10.1056/nejm199705223362107PubMedCrossRef
36.
go back to reference Kearon C (2003) Natural history of venous thromboembolism. Circulation 107:I-22-30, 10.1161/01.cir.0000078464.82671.78 Kearon C (2003) Natural history of venous thromboembolism. Circulation 107:I-22-30, 10.1161/01.cir.0000078464.82671.78
37.
go back to reference Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS (1998) Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279:458–462, 10.1001/jama.279.6.458PubMedCrossRef Douketis JD, Kearon C, Bates S, Duku EK, Ginsberg JS (1998) Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. JAMA 279:458–462, 10.1001/jama.279.6.458PubMedCrossRef
Metadata
Title
Effectiveness and safety of a management protocol to correct over-anticoagulation with oral vitamin K: a retrospective study of 1,043 cases
Authors
G. Denas
F. Marzot
P. Offelli
A. Stendardo
U. Cucchini
R. Russo
G. Nante
S. Iliceto
Vittorio Pengo
Publication date
01-04-2009
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2009
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-008-0211-4

Other articles of this Issue 3/2009

Journal of Thrombosis and Thrombolysis 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.